Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06417814 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of Metastatic Non Small Cell Lung Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 744
- Enrollment target
- 20
- Study locations
NCT06417814: Recruiting Phase 3 study of Metastatic Non Small Cell Lung Cancer, sponsored by AstraZeneca.
NCT06417814 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 744 participants, above the 358-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (108% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06417814, a Phase 3 study of Metastatic Non Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 744 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Primary Outcome
PFS is defined as the time from randomization to Blinded Independent Central Review (BICR)-assessed progression using RECIST v1.1 or death due to any cause, regardless of whether the participant withdraws from study therapy, receives other anti-cancer therapy, or clinical progression.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Osimertinib
- DRUG Pemetrexed
- DRUG Dato-DXd
Study Locations (20)
California
- Research Site - Duarte
- Research Site - Fountain Valley
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - San Diego
Massachusetts
- Research Site - Boston
- Research Site - Boston
- Research Site - Boston
Colorado
- Research Site - Colorado Springs
- Research Site - Fort Collins
Florida
- Research Site - Gainesville
- Research Site - Jacksonville
Illinois
- Research Site - Chicago
- Research Site - Evanston
Maryland
- Research Site - Baltimore
- Research Site - Bethesda
Arkansas
- Research Site - Fayetteville
Georgia
- Research Site - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2024-10-04 |
| Est. Completion | 2028-09-27 |
| Phase | Phase 3 |
What NCT06417814 shows while recruiting
NCT06417814 is an interventional study that assigns participants to a tested intervention. The registered 744 participants enrollment target is mid-sized for trials with a published cap, above the 358-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (108% higher).
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06417814 names 20 study sites across 10 states, led by California, Massachusetts, Colorado.
Frequently Asked Questions
What is clinical trial NCT06417814 about?
NCT06417814 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer". This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
What is the current status of trial NCT06417814?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 744 participants. The study started on 2024-10-04. Estimated completion is 2028-09-27.
What conditions does trial NCT06417814 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT06417814?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Osimertinib (DRUG), Pemetrexed (DRUG), Dato-DXd (DRUG).
Who is sponsoring clinical trial NCT06417814?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06417814 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06417814's enrollment target sits among peer trials
744 5th of 31 higher than 27 of 31 other Metastatic Non Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Non Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RECRUITING · Phase 3
-
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RECRUITING · Phase 3
-
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI